Innate and adaptive immune control of genetically engineered live-attenuated arenavirus vaccine prototypes

International Immunology

Volumn 22, Issue 9, 2010, Pages 749-756

  Pinschewer, Daniel D ^a,b   Flatz, Lukas ^a,b,c   Steinborn, Ralf ^d   Horvath, Edit ^b   Fernandez, Marylise ^a   Lutz, Hans ^e   Suter, Mark ^e   Bergthaler, Andreas ^a,b,f  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b INSTITUTE OF EXPERIMENTAL IMMUNOLOGY   (Switzerland)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d UNIVERSITY OF VETERINARY MEDICINE   (Austria)

^e UNIVERSITY OF ZURICH   (Switzerland)

^f INSTITUTE FOR SYSTEMS BIOLOGY   (United States)

Author keywords

Arenavirus; Lassa fever; Live attenuation; Lymphocytic choriomeningitis virus; Vaccine

Indexed keywords

ALPHA INTERFERON; LYMPHOCYTIC CHORIOMENINGITIS VIRUS VACCINE; UNCLASSIFIED DRUG; VIRUS RNA; VIRUS VACCINE;

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; INNATE IMMUNITY; LYMPHOCYTIC CHORIOMENINGITIS; MEMORY T LYMPHOCYTE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; VIREMIA; VIRUS LOAD;

ADAPTIVE IMMUNITY; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; GENES, RAG-1; IMMUNITY, INNATE; IMMUNOLOGIC MEMORY; LASSA FEVER; LASSA VIRUS; MICE; MICE, INBRED C57BL; ORGANISMS, GENETICALLY MODIFIED; RECEPTOR, INTERFERON ALPHA-BETA; RECEPTORS, INTERFERON; VACCINES, ATTENUATED; VIRAL VACCINES;

EID: 77956126189     PISSN: 09538178     EISSN: 14602377     Source Type: Journal    
DOI: 10.1093/intimm/dxq061     Document Type: Article

References (47)

1. Plotkin, S. A. 2005. Vaccines: past, present and future. Nat. Med. 11:S5.
2. McCormick, J. B., Webb, P. A., Krebs, J. W., Johnson, K. M. and Smith, E. S. 1987. A prospective study of the epidemiology and ecology of Lassa fever. J. Infect. Dis. 155:437.
3. Borio, L., Inglesby, T., Peters, C. J. et al. 2002. Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA 287:2391.
4. Maiztegui, J. I., McKee, K. T. Jr., Barrera Oro, J. G. et al. 1998. Protective efficacy of a live attenuated vaccine against Argentine hemorrhagic fever. AHF Study Group. J. Infect. Dis. 177:277.
5. Berzofsky, J. A., Ahlers, J. D. and Belyakov, I. M. 2001. Strategies for designing and optimizing new generation vaccines. Nat. Rev. Immunol. 1:209.
6. Zinkernagel, R. M. 2003. On natural and artificial vaccinations. Annu. Rev. Immunol. 21:515.
7. Theiler, M. and Smith, H. H. 2000. The use of yellow fever virus modified by in vitro cultivation for human immunization. J. Exp. Med. 65:787. (1937). Rev. Med. Virol. 10:6-16; discussion 3-5.
8. Rodriguez-Carreno, M. P., Nelson, M. S., Botten, J., Smith-Nixon, K., Buchmeier, M. J. and Whitton, J. L. 2005. Evaluating the immunogenicity and protective efficacy of a DNA vaccine encoding Lassa virus nucleoprotein. Virology 335:87.
9. Djavani, M., Yin, C., Lukashevich, I. S., Rodas, J., Rai, S. K. and Salvato, M. S. 2001. Mucosal immunization with Salmonella typhimurium expressing Lassa virus nucleocapsid protein cross-protects mice from lethal challenge with lymphocytic choriomeningitis virus. J. Hum. Virol. 4:103.
10. Pushko, P., Geisbert, J., Parker, M., Jahrling, P. and Smith, J. 2001. Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses. J. Virol. 75:11677.
11. Geisbert, T. W., Jones, S., Fritz, E. A. et al. 2005. Development of a new vaccine for the prevention of Lassa fever. PLoS Med. 2:e183.
12. Lukashevich, I. S., Patterson, J., Carrion, R. et al. 2005. A live attenuated vaccine for Lassa fever made by reassortment of Lassa and Mopeia viruses. J. Virol. 79:13934.
13. Flatz, L., Bergthaler, A., de la Torre, J. C. and Pinschewer, D. D. 2006. Recovery of an arenavirus entirely from RNA polymerase I/II-driven cDNA. Proc. Natl Acad. Sci. USA 103:4663.
14. Sanchez, A. B. and de la Torre, J. C. 2006. Rescue of the prototypic arenavirus LCMV entirely from plasmid. Virology 350:370.
15. Bergthaler, A., Gerber, N. U., Merkler, D., Horvath, E., de la Torre, J. C. and Pinschewer, D. D. 2006. Envelope exchange for the generation of live-attenuated arenavirus vaccines. PLoS Pathog. 2:e51.
16. Pinschewer, D. D., Perez, M., Jeetendra, E. et al. 2004. Kinetics of protective antibodies are determined by the viral surface antigen. J. Clin. Invest. 114:988.
17. Pinschewer, D. D., Perez, M., Sanchez, A. B. and de la Torre, J. C. 2003. Recombinant lymphocytic choriomeningitis virus expressing vesicular stomatitis virus glycoprotein. Proc. Natl Acad. Sci. USA 100:7895.
18. Zuniga, E. I., Hahm, B. and Oldstone, M. B. 2007. Type I interferon during viral infections: multiple triggers for a multifunctional mediator. Curr. Top. Microbiol. Immunol. 316:337.
19. Kabelitz, D. and Medzhitov, R. 2007. Innate immunity-cross-talk with adaptive immunity through pattern recognition receptors and cytokines. Curr. Opin. Immunol. 19:1.
20. Gaucher, D., Therrien, R., Kettaf, N. et al. 2008. Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J. Exp. Med. 205:3119.
21. Querec, T. D., Akondy, R. S., Lee, E. K. et al. 2009. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat. Immunol. 10:116.
22. van den Broek, M. F., Muller, U., Huang, S., Aguet, M. and Zinkernagel, R. M. 1995. Antiviral defense in mice lacking both alpha/beta and gamma interferon receptors. J. Virol. 69:4792.
23. Mombaerts, P., Iacomini, J., Johnson, R. S., Herrup, K., Tonegawa, S. and Papaioannou, V. E. 1992. RAG-1-deficient mice have no mature B and T lymphocytes. Cell 68:869.
24. Vollstedt, S., Arnold, S., Schwerdel, C. et al. 2004. Interplay between alpha/beta and gamma interferons with B, T, and natural killer cells in the defense against herpes simplex virus type 1. J. Virol. 78:3846.
25. Grob, P., Schijns, V. E., van den Broek, M. F., Cox, S. P., Ackermann, M. and Suter, M. 1999. Role of the individual interferon systems and specific immunity in mice in controlling systemic dissemination of attenuated pseudorabies virus infection. J. Virol. 73:4748
26. Zinkernagel, R. M., Leist, T., Hengartner, H. and Althage, A. 1985. Susceptibility to lymphocytic choriomeningitis virus isolates correlates directly with early and high cytotoxic T cell activity, as well as with footpad swelling reaction, and all three are regulated by H-2D. J. Exp. Med. 162:2125.
27. Battegay, M., Cooper, S., Althage, A., Banziger, J., Hengartner, H. and Zinkernagel, R. M. 1991. Quantification of lymphocytic choriomeningitis virus with an immunological focus assay in 24- or 96-well plates. J. Virol. Methods 33:191.
28. Muller, S., Hunziker, L., Enzler, S. et al. 2002. Role of an intact splenic microarchitecture in early lymphocytic choriomeningitis virus production. J. Virol. 76:2375.
29. Ciurea, A., Klenerman, P., Hunziker, L. et al. 2000. Viral persistence in vivo through selection of neutralizing antibody-escape variants. Proc. Natl Acad. Sci. USA 97:2749.
30. Boyman, O., Hefti, H. P., Conrad, C., Nickoloff, B. J., Suter, M. and Nestle, F. O. 2004. Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-alpha. J. Exp. Med. 199:731.
31. Fernandez, N. C., Lozier, A., Flament, C. et al. 1999. Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat. Med. 5:405.
32. Lee, C. K., Rao, D. T., Gertner, R., Gimeno, R., Frey, A. B. and Levy, D. E. 2000. Distinct requirements for IFNs and STAT1 in NK cell function. J. Immunol. 165:3571.
33. Merkler, D., Horvath, E., Bruck, W., Zinkernagel, R. M., Del la Torre, J. C. and Pinschewer, D. D. 2006. "Viral deja vu" elicits organ-specific immune disease independent of reactivity to self. J. Clin. Invest. 116:1254.
34. Aichele, P., Unsoeld, H., Koschella, M., Schweier, O., Kalinke, U. and Vucikuja, S. 2006. CD8 T cells specific for lymphocytic choriomeningitis virus require type I IFN receptor for clonal expansion. J. Immunol. 176:4525.
35. Fink, K., Lang, K. S., Manjarrez-Orduno, N. et al. 2006. Early type I interferon-mediated signals on B cells specifically enhance antiviral humoral responses. Eur. J. Immunol. 36:2094.
36. Kolumam, G. A., Thomas, S., Thompson, L. J., Sprent, J. and Murali-Krishna, K. 2005. Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection. J. Exp. Med. 202:637.
37. Thompson, L. J., Kolumam, G. A., Thomas, S. and Murali-Krishna, K. 2006. Innate inflammatory signals induced by various pathogens differentially dictate the IFN-I dependence of CD8 T cells for clonal expansion and memory formation. J. Immunol. 177:1746.
38. Baenziger, J., Hengartner, H., Zinkernagel, R. M. and Cole, G. A. 1986. Induction or prevention of immunopathological disease by cloned cytotoxic T cell lines specific for lymphocytic choriome-ningitis virus. Eur. J. Immunol. 16:387.
39. Wilson, C. B. and Marcuse, E. K. 2001. Vaccine safety-vaccine benefits: science and the public's perception. Nat. Rev. Immunol. 1:160.
40. de la Torre, J. C. 2009. Molecular and cell biology of the prototypic arenavirus LCMV: implications for understanding and combating hemorrhagic fever arenaviruses. Ann. N. Y. Acad. Sci. 1171 (Suppl 1):E57.
41. Louten, J., van Rooijen, N. and Biron, C. A. 2006. Type 1 IFN deficiency in the absence of normal splenic architecture during lymphocytic choriomeningitis virus infection. J. Immunol. 177:3266.
42. Cousens, L. P., Peterson, R., Hsu, S. et al. 1999. Two roads diverged: interferon alpha/beta- and interleukin 12-mediated pathways in promoting T cell interferon gamma responses during viral infection. J. Exp. Med. 189:1315.
43. Neuman, B. W., Adair, B. D., Burns, J. W., Milligan, R. A., Buchmeier, M. J. and Yeager, M. 2005. Complementarity in the supramolecular design of arenaviruses and retroviruses revealed by electron cryomicroscopy and image analysis. J. Virol. 79:3822.
44. Perez, M., Craven, R. C. and de la Torre, J. C. 2003. The small RING finger protein Z drives arenavirus budding: implications for antiviral strategies. Proc. Natl Acad. Sci. USA 100:12978.
45. Chen, S. T., Iida, A., Guo, L., Friedmann, T. and Yee, J. K. 1996. Generation of packaging cell lines for pseudotyped retroviral vectors of the G protein of vesicular stomatitis virus by using a modified tetracycline inducible system. Proc. Natl Acad. Sci. USA 93:10057.
46. Fischer, S. A., Graham, M. B., Kuehnert, M. J. et al. 2006. Transmission of lymphocytic choriomeningitis virus by organ transplantation. N. Engl. J. Med. 354:2235.
47. Flatz, L., Hegazy, A. N., Bergthaler, A. et al. 2010. Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8+ T cell immunity. Nat. Med. 16:339.